Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (3): 258-264.DOI: 10.3969/j.issn.1673-8640.2026.03.008
Previous Articles Next Articles
Received:2024-12-17
Revised:2025-11-07
Online:2026-03-30
Published:2026-04-14
Contact:
ZHOU Mo
CLC Number:
SHAO Yu, WANG Pin, ZHOU Mo. Role of serum lncRNA HOTTIP and lncRNA HULC expression in multiple myeloma monitoring and prognosis judgement[J]. Laboratory Medicine, 2026, 41(3): 258-264.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.03.008
| 基因名称 | 正向引物(5'~3') | 反向引物(5'~3') |
|---|---|---|
| lncRNA HOTTIP | CCTAAAGCCACGCTTCTTTG | TGCAGGCTGGAGATCCTAGT |
| lncRNA HULC | ACCTCCAGAACTGTGATCCAAAATG | GCCAGGAAACTTCTTGCTTGA |
| GAPDH | CTGTACAGCCGCTTAAGCACG | CGTGACGCCTACGTACCGTAC |
| 基因名称 | 正向引物(5'~3') | 反向引物(5'~3') |
|---|---|---|
| lncRNA HOTTIP | CCTAAAGCCACGCTTCTTTG | TGCAGGCTGGAGATCCTAGT |
| lncRNA HULC | ACCTCCAGAACTGTGATCCAAAATG | GCCAGGAAACTTCTTGCTTGA |
| GAPDH | CTGTACAGCCGCTTAAGCACG | CGTGACGCCTACGTACCGTAC |
| 组别 | 例数 | lncRNA HOTTIP | lncRNA HULC |
|---|---|---|---|
| Ⅰ期组 | 20 | 1.13±0.11 | 1.16±0.12 |
| Ⅱ期组 | 31 | 1.21±0.14* | 1.24±0.11* |
| Ⅲ期组 | 16 | 1.33±0.12*# | 1.38±0.16*# |
| F值 | 11.045 | 13.654 | |
| P值 | <0.001 | <0.001 |
| 组别 | 例数 | lncRNA HOTTIP | lncRNA HULC |
|---|---|---|---|
| Ⅰ期组 | 20 | 1.13±0.11 | 1.16±0.12 |
| Ⅱ期组 | 31 | 1.21±0.14* | 1.24±0.11* |
| Ⅲ期组 | 16 | 1.33±0.12*# | 1.38±0.16*# |
| F值 | 11.045 | 13.654 | |
| P值 | <0.001 | <0.001 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA HOTTIP | 0.830(0.743~0.897) | 1.25 | 68.75 | 84.99 | 0.537 |
| lncRNA HULC | 0.852(0.769~0.915) | 1.28 | 75.00 | 77.91 | 0.529 |
| 联合检测 | 0.910(0.860~0.949) | 0.42 | 81.25 | 90.70 | 0.720 |
| 项目 | AUC(95%CI①) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA HOTTIP | 0.830(0.743~0.897) | 1.25 | 68.75 | 84.99 | 0.537 |
| lncRNA HULC | 0.852(0.769~0.915) | 1.28 | 75.00 | 77.91 | 0.529 |
| 联合检测 | 0.910(0.860~0.949) | 0.42 | 81.25 | 90.70 | 0.720 |
| 项目 | 单因素分析 | 多因素分析 | |||
|---|---|---|---|---|---|
| HR①值(95%CI) | P值 | HR值(95%CI) | P值 | ||
| ISS分期 | 1.393(1.126~1.302) | 0.016 | 1.518(1.133~2.286) | <0.001 | |
| lncRNA HOTTIP | 1.842(1.370~2.236) | <0.001 | 1.771(1.255~2.388) | <0.001 | |
| lncRNA HULC | 2.304(1.433~2.602) | <0.001 | 2.012(1.672~2.921) | <0.001 | |
| 项目 | 单因素分析 | 多因素分析 | |||
|---|---|---|---|---|---|
| HR①值(95%CI) | P值 | HR值(95%CI) | P值 | ||
| ISS分期 | 1.393(1.126~1.302) | 0.016 | 1.518(1.133~2.286) | <0.001 | |
| lncRNA HOTTIP | 1.842(1.370~2.236) | <0.001 | 1.771(1.255~2.388) | <0.001 | |
| lncRNA HULC | 2.304(1.433~2.602) | <0.001 | 2.012(1.672~2.921) | <0.001 | |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA HOTTIP | 0.850(0.787~0.899) | 1.28 | 79.93 | 88.37 | 0.593 |
| lncRNA HULC | 0.873(0.847~0.941) | 2.30 | 81.40 | 87.20 | 0.686 |
| 联合检测 | 0.937(0.890~0.969) | 0.45 | 91.86 | 80.23 | 0.721 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| lncRNA HOTTIP | 0.850(0.787~0.899) | 1.28 | 79.93 | 88.37 | 0.593 |
| lncRNA HULC | 0.873(0.847~0.941) | 2.30 | 81.40 | 87.20 | 0.686 |
| 联合检测 | 0.937(0.890~0.969) | 0.45 | 91.86 | 80.23 | 0.721 |
| [1] | RAJKUMAR S V. Multiple myeloma:every year a new standard?[J]. Hematol Oncol, 2019, 37(Suppl 1):62-65. |
| [2] |
BRIGLE K, ROGERS B. Pathobiology and diagnosis of multiple myeloma[J]. Semin Oncol Nurs, 2017, 33(3):225-236.
DOI PMID |
| [3] |
沈希敏, 张雷, 权衡, 等. 血清lncRNA NEAT1在多发性骨髓瘤患者肾损伤的临床应用价值分析[J]. 检验医学, 2025, 40(1):32-36.
DOI |
| [4] | 张永梅, 张志敏, 周洁, 等. LncRNA CBR3-AS1在多发性骨髓瘤中的表达及临床意义[J]. 基础医学与临床, 2023, 43(6):948-952. |
| [5] | 张琳, 郑倩婧, 刘亚飞, 等. 血清lncRNA HOTTIP表达对胰腺癌患者的诊断及预后意义[J]. 现代消化及介入诊疗, 2021, 26(10):1239-1242. |
| [6] | LIU J, YANG L, LIU X, et al. LncRNA HOTTIP recruits EZH2 to inhibit PTEN expression and participates in IM resistance in chronic myeloid leukemia[J]. Stem Cells Int, 2022, 2022:9993393. |
| [7] | ZENG X, DONG Q, LIU Q, et al. LncRNA HOTTIP facilitates osteogenic differentiation in bone marrow mesenchymal stem cells and induces angiogenesis via interacting with TAF15 to stabilize DLX2[J]. Exp Cell Res, 2022, 417(2):113226. |
| [8] |
冀叶, 袁小笋, 张蕾, 等. lncRNA HULC在乳头状甲状腺癌组织中的表达及意义[J]. 检验医学, 2022, 37(7):605-609.
DOI |
| [9] | 何晓薇, 吴斌, 孙颖, 等. LncRNA HULC通过调控NF-κB信号通路对淋巴瘤细胞增殖和凋亡的影响[J]. 中国临床药理学杂志, 2022, 38(14):1628-1632. |
| [10] | 李梦, 周云, 禹亚彬, 等. 长链非编码RNA肝癌高表达转录本促进人骨髓间充质干细胞向肝样细胞的分化[J]. 中国组织工程研究, 2019, 23(29):4656-4661. |
| [11] | 沈悌, 赵永强. 血液病诊断及疗效标准[M]. 4版. 北京: 科学出版社, 2018. |
| [12] |
GUZDAR A, COSTELLO C. Supportive care in multiple myeloma[J]. Curr Hematol Malig Rep, 2020, 15(2):56-61.
DOI |
| [13] |
PAWLYN C, DAVIES F E. Toward personalized treatment in multiple myeloma based on molecular characteristics[J]. Blood, 2019, 133(7):660-675.
DOI PMID |
| [14] |
LEVIN A, HARI P, DHAKAL B. Novel biomarkers in multiple myeloma[J]. Transl Res, 2018, 201:49-59.
DOI PMID |
| [15] |
CAERS J, GARDERET L, KORTÜM K M, et al. European myeloma network recommendations on tools for the diagnosis and monitoring of multiple myeloma:what to use and when[J]. Haematologica, 2018, 103(11):1772-1784.
DOI URL |
| [16] | 赵晶, 刘海波, 习杰英. 多发性骨髓瘤患者中LncRNA DAPK1-IT1的表达与其临床意义研究[J]. 临床血液学杂志, 2022, 35(3):190-194. |
| [17] | 刘海燕. LncRNA-TCF7在多发性骨髓瘤中的表达及作用机制研究[D]. 苏州: 苏州大学, 2022. |
| [18] | 姚蓝. ALKBH5通过调控lncRNA SNHG15表达促进多发性骨髓瘤发病的机制研究[D]. 武汉: 华中科技大学, 2021. |
| [19] | 沈珠花, 徐永灿, 乔鹏. LncRNA HOTTIP在胃癌D2根治术后肿瘤复发、耐药及预后中的作用[J]. 中国现代医生, 2022, 60(13):42-46. |
| [20] | 吕梦, 王健. 血浆CA19-9、lncRNA HOTTIP水平对胰腺癌的诊断价值[J]. 山东医药, 2021, 61(10):21-25. |
| [21] | 陈存宝, 肖瑞雪, 李建祺, 等. LncRNA HULC在结直肠癌组织中的表达及临床意义(附50例)[J]. 现代肿瘤医学, 2023, 31(20):3796-3800. |
| [22] | 王慧娜, 张静, 李月. 肝癌患者血清lncRNA HULC表达水平与肿瘤分期、淋巴结转移的关系[J]. 华夏医学, 2023, 36(2):76-79. |
| [1] | ZHANG Lan, ZHU Jianfeng, PAN Baishen, CHEN Pu, WANG Beili, GUO Wei. Prognostic value of circulating plasma cells determined by morphology in newly diagnosed multiple myeloma [J]. Laboratory Medicine, 2025, 40(1): 15-19. |
| [2] | SHEN Ximin, ZHANG Lei, QUAN Heng, NIU Ziguang, XIA Dongge, ZHANG Rulin. Clinical significance of serum lncRNA NEAT1 for multiple myeloma patients with kidney injury [J]. Laboratory Medicine, 2025, 40(1): 32-36. |
| [3] | MA Liyuan, YU Xiaohui, ZHANG Ningyu. Relation between peripheral blood cell score combined with IL-32 and prognosis of patients undergoing surgical treatment for multiple myeloma [J]. Laboratory Medicine, 2024, 39(5): 458-463. |
| [4] | WANG Hongling, LI Li, ZHANG Chunling, LIN Lihui, DING Jing, LI Huidan, WEI Daolin, BAI Ping. Retrospective clinical analysis of κ light chain multiple myeloma with cytoplasmic granules [J]. Laboratory Medicine, 2021, 36(8): 818-822. |
| [5] | CHEN Xia, CHEN Xi. Clinical significance of plasma protein C and von Willebrand factor in patients with multiple myeloma [J]. Laboratory Medicine, 2021, 36(11): 1110-1113. |
| [6] | ZHENG Wei, LU Jie, GUI Qingrong, WANG Dongyun. Laboratory examination results and clinical characteristics of 28 cases of IgD multiple myeloma [J]. Laboratory Medicine, 2020, 35(3): 224-228. |
| [7] | XU Kaihong, MU Qitian, OUYANG Guifang, YAN Xiao. Cytogenetic analysis of 153 newly-diagnosed cases of multiple myeloma [J]. Laboratory Medicine, 2020, 35(12): 1243-1247. |
| [8] | ZHENG Wei, LU Jie, HAO Aijun, ZHANG Yinhui. Analysis on the laboratory examination results of 5 cases of diclonal multiple myeloma [J]. Laboratory Medicine, 2019, 34(8): 710-716. |
| [9] | ZHANG Jingyu, FAN Hong, LU Bingtong, HU Haitao. Serum immunoglobulin and other factors on the effect of blood separating in separator gel tubes [J]. Laboratory Medicine, 2018, 33(4): 275-278. |
| [10] | JI Wei, WU Hongkun, ZHOU Lin. Research progress of non-coding RNA in multiple myeloma [J]. Laboratory Medicine, 2018, 33(3): 264-268. |
| [11] | ZHANG Jingyu, CHEN Lixin, WANG Lifang, HU Haitao, WANG Jun, FAN Hong. Influence of serum IgA level on serum fructosamine level [J]. Laboratory Medicine, 2017, 32(3): 182-184. |
| [12] | LIU Shuai, LI Zhaobo, ZHANG Fan, WANG Ningning, YUE Baohong. Plasmocyte immuno-phenotype characteristics of 37 cases of CD45-positive multiple myeloma [J]. Laboratory Medicine, 2017, 32(2): 76-80. |
| [13] | HE Yali, LIANG Shunrong, FAN Jiaxin. Changes of serum β2-MG and LDH in combination therapy of multiple myeloma with honokiol and arsenic trioxide [J]. Laboratory Medicine, 2016, 31(6): 449-452. |
| [14] | WANG Wei.. The laboratory characteristics of multiple myeloma [J]. Laboratory Medicine, 2015, 30(8): 847-851. |
| [15] | CHONG Huifeng, SUN Yun, WANG Chuanfa, WANG Yaqin, CAO Chunluan, ZHOU Ping. Significance comparison of immunofixation electrophoresis and bone marrow cell morphology examination in clinical typing of multiple myeloma [J]. Laboratory Medicine, 2015, 30(7): 720-722. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
